Addex Therapeutics (STU:APE1) FFO


STU:APE1 Addex Therapeutics Ltd STU:APE1
52 GF Score
Price €4.86
GF Value €1.13
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:APE1
52GF Score
Addex Therapeutics Ltd STU:APE1
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Addex Therapeutics (STU:APE1) Overvalued in 2026?

Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued. The current stock price of €4.86 is trading 330.1% above its estimated GF Value™ of €1.13.

Key valuation signals for STU:APE1:

  • FFO:
  • GF Value™: €1.13 vs. price of €4.86 (330.1% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the STU:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
52GF Score

Get the complete analysis for STU:APE1

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.86
Price
€1.13
GF Value